Development, production, and commercialization of high therapeutic value pharmaceutical solutions across multiple therapeutic areas.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: May 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Viatris
A
Development and commercialization of generic, established brand, and innovative medicines across various therapeutic areas.
Takeda
B
Development and commercialization of innovative medicines in various therapeutic areas, including gastrointestinal diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
Global Pharma
B
Production and distribution of pharmaceutical formulations in various therapeutic forms.
Initiatives identified among leaders
Politiques globales pour pratiques environnementales, santé et sécurité.
“Viatris a établi plusieurs politiques mondiales en...” - ViatrisPromotion des droits de l'homme
“Takeda promeut les droits de l'homme dans toutes l...” - TakedaProgrammes éducatifs et ESG pour renforcer les communautés locales.
“Mise en œuvre d'initiatives éducatives et de progr...” - Global Pharma65% of similar organizations communicate on CSR issues
+542 initiatives collected from 49 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports